Navigation Links
Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Maryland's Emerging Company of the Year Award
Date:5/19/2008

ROCKVILLE, Md., May 19 /PRNewswire-USNewswire/ -- On Thursday May 15, 2008 Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration honoring the state's technology leaders and organizations.

http://techcouncilmd.com/News/tcmnews_080516.html

"All the members of the Sanaria team go to work every day with only one goal in mind, to develop a vaccine that will prevent millions of deaths from malaria," said Sanaria founder and CEO, Stephen L. Hoffman. "I am honored to accept this award on their behalf, and on behalf of our partners who have invested so much in us."

The PATH Malaria Vaccine Initiative, which is partnering with Sanaria Inc. to accelerate development of the company's novel malaria vaccine candidate, welcomed the news. "We at MVI are pleased at the recognition of our partner's efforts to establish a core platform technology for producing attenuated sporozoite malaria vaccines," said Director Dr. Christian Loucq.

The annual dinner and awards celebration was attended by Maryland Governor Martin O'Malley, additional state and local government representatives, and over 900 members of the Maryland technology and biotech industries.

About Sanaria Inc., The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-lookin
'/>"/>

SOURCE Sanaria Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
2. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
3. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
4. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
5. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
11. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... RNL Bio Co., Ltd, ( www.rnl.co.kr ) a ... therapeutics announced today that a 46-year-old female, Kang ... stem cell treatment. Park was suffering from MS ... central nervous system (brain and spinal cord). ... the nerves of the central nervous system degenerate. ...
(Date:12/4/2009)... 4 Thermographic Diagnostic Imaging (TDI), part of ... Jersey continues to provide superior quality infrared imaging ... and sinus regions to assist in the early ... ,, Thermography utilizes infrared imaging cameras that "read" ...
(Date:12/4/2009)... Inc. (Nasdaq: ONXX ) today announced that it ... investigators will discuss the data presentations surrounding carfilzomib in ... 51st American Society of Hematology (ASH) Annual Meeting. ,, ... ET on Monday, December 7, 2009. The live ...
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2Discover Health Through Awareness 2Discover Health Through Awareness 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Key Protein Might Shield Brain Cells 51813 1Michael Steele Chairman of the Republican National Committee Will Hold a Press Conference on Health Care the Republican Alternative at 9 am on Mon 51810 1Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer 51807 1Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer 51807 2
... about their ... risks, ... (2007), an estimated 182,460 new cases of breast,cancer will be diagnosed in ... detection of the disease when it is,more easily and successfully treated, breast ...
... Advantages ... Over Existing Once-Daily Product, NOTTINGHAM, England, ... today announced that the successful completion of preclinical,trials of ... (hGH) somatropin. Trials demonstrated therapeutic plasma,concentrations were achieved over ...
Other Medicine Technology:Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 2Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 3Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 4Critical Pharmaceuticals Enter Sustained Release hGH Arena 2
(Date:12/7/2009)... -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... St. George,s Hospital, University of London during a ... ("ASH") Annual Meeting updated results from the pivotal ... pixantrone (the "PIX 301 EXTEND trial") in relapsed ... who have failed 2 or more prior therapies. ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... of feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay ... might be found in a tiger that lived thousands or ... appears the virus took on a bit of a tiger,s ... remains in the virus to this day. That tiger, in ... of the virus that ultimately led to its infection of ...
(Date:12/6/2009)... Hamilton, ON. Dec. 6, 2009 A new study ... disorder known as venous thromboembolism (VTE). , The ... Americans every year, and occurs when an abnormal clot ... blood, causing pain and swelling. In some cases, the ... travel through the heart to the lungs, causing a ...
(Date:12/5/2009)... ORLEANS, Dec. 5 There have been significant scientific ... experts continue to gain a better understanding of how ... options and provide patients with the best care. Research ... American Society of Hematology explores optimal induction therapies for ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... pulmonary arterial hypertension (PAH)chronically high blood pressure in the ... low (called hyponatremia, or HN) have a very poor ... failure (RHF), according to new research from the University ... known to indicate advanced left heart failure but has ...
... of Lower Manhattan, the terrorist attacks of September 11, ... by the Health Department,s World Trade Center Health Registry, ... had posttraumatic stress disorder (PTSD) two to three years ... residents developed PTSD at three times the usual rate ...
... Valuable Patient Care,Resources in Manner True to Their Mission, ... from Los Angeles and Orange Counties demonstrated in front ... Thursday, June 12th to protest the,firm,s anti-union tactics aimed ... System (SJHS), a $3.4 billion dollar corporation,founded by the ...
... Bipartisan Package Would Have Improved Benefits for Prevention, ... CHICAGO, June 12 Today a minority ... and improve Medicare,for the 44 million Americans who ... Providers Act, which would have improved Medicare,s,prevention, mental ...
... A University of Alberta researcher in collaboration with researchers ... come with age, at least when it comes to ... Dolcos, assistant professor of psychiatry and neuroscience in the ... help healthy older people regulate and control emotion better ...
... (NYSE: GRB ), a worldwide leader in integrated ... investors on,Thursday, June 19, 2008, at 10:00 a.m. (Eastern ... financial results and provide a Company,update. The Company will ... and full year on June 19, 2008 before the ...
Other Medicine News:Health News:Serum sodium predicts mortality 10 times higher in PAH patients 2Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 3Health News:AARP Disappointed by U.S. Senate Vote to Block Medicare Improvement Bill 2Health News:AARP Disappointed by U.S. Senate Vote to Block Medicare Improvement Bill 3Health News:New research shows how aging brain brings a healthy dose of perspective 2Health News:Gerber Scientific to Hold Fiscal Year 2008 Fourth Quarter and Full Year Conference Call 2
...
... catheter is made of two probes which ... of sensor distance., ,VersaFlex disposable catheters ... ,Alpine's VersaFlex catheters are the smallest diameter ... and are the perfect combination of flexibility ...
... catheters are efficient, economical, eliminate the ... patient comfort during the test period., ... have been designed to use temperature ... room-temperature calibration. The temperature correction factors ...
FLEXILOG spare part....
Medicine Products: